The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PCVX | -23.25% | +113.08% | +16.32% | +120% |
| S&P | +19.17% | +69.21% | +11.09% | +119% |
Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering, and Jeff Fairman on November 27, 2013 and is headquartered in San Carlos, CA.
Focused on next-generation vaccines for bacterial diseases, this biotech just reported a notable insider sale amid a challenging year.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$9,800.00K | -104.8% |
| Market Cap | $6.04B | -40.8% |
| Market Cap / Employee | $11.91M | 0.0% |
| Employees | 507 | 22.5% |
| Net Income | -$246,507.00K | -79.8% |
| EBITDA | -$264,483.00K | -68.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $173.96M | -55.2% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $111.36M | 70.7% |
| Short Term Debt | $6.12M | 4.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -23.30% | -4.5% |
| Return On Invested Capital | -25.69% | 15.9% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$233,253.00K | -64.9% |
| Operating Free Cash Flow | -$224,832.00K | -101.8% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.43 | 1.31 | 1.52 | 2.07 | -30.42% |
| Price to Tangible Book Value | 1.43 | 1.31 | 1.52 | 2.07 | -30.42% |
| Enterprise Value to EBITDA | -20.12 | -12.87 | -13.82 | -17.41 | -67.95% |
| Return on Equity | -19.7% | -21.7% | -20.8% | -25.6% | 25.39% |
| Total Debt | $87.21M | $85.85M | $84.44M | $117.48M | 65.21% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
